- Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon
- Novocure Reports First Quarter 2024 Financial Results
- Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
- Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024
- Novocure to Report First Quarter 2024 Financial Results
- Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
- METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
- INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO
More ▼
Key statistics
As of last trade, Novocure Ltd (NVCR:NSQ) traded at 22.95, 111.13% above the 52 week low of 10.87 set on Nov 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 23.49 |
---|---|
High | 23.49 |
Low | 22.86 |
Bid | 22.89 |
Offer | 23.01 |
Previous close | 23.70 |
Average volume | 1.76m |
---|---|
Shares outstanding | 107.61m |
Free float | 97.65m |
P/E (TTM) | -- |
Market cap | 2.55bn USD |
EPS (TTM) | -1.81 USD |
Data delayed at least 15 minutes, as of May 23 2024 14:40 BST.
More ▼